Blood speaks: Personalised medicine profiling for heart failure patients.
作者信息
Firouzi Fareheh, Sussman Mark A
机构信息
SDSU Heart Institute and Department of Biology, San Diego State University, San Diego, CA, United States.
SDSU Heart Institute and Department of Biology, San Diego State University, San Diego, CA, United States.
出版信息
EBioMedicine. 2020 Aug;58:102900. doi: 10.1016/j.ebiom.2020.102900. Epub 2020 Jul 22.
Abstract
摘要
相似文献
1
Blood speaks: Personalised medicine profiling for heart failure patients.血液发声：心力衰竭患者的个性化医疗剖析
EBioMedicine. 2020 Aug;58:102900. doi: 10.1016/j.ebiom.2020.102900. Epub 2020 Jul 22.
2
[A health passport for patients with heart failure].[心力衰竭患者的健康护照]
Soins. 2017 Nov;62(820):43-44. doi: 10.1016/j.soin.2017.09.010.
3
Risk stratification personalised model for prediction of life-threatening ventricular tachyarrhythmias in patients with chronic heart failure.用于预测慢性心力衰竭患者危及生命的室性快速心律失常的风险分层个性化模型。
Kardiol Pol. 2017;75(7):682-688. doi: 10.5603/KP.a2017.0060.
4
Perspective on precision medicine in paediatric heart failure.小儿心力衰竭精准医学的展望
Clin Sci (Lond). 2017 Mar 1;131(6):439-448. doi: 10.1042/CS20160414.
5
Precision Medicine for Heart Failure: Back to the Future.心力衰竭的精准医学：回归未来。
J Am Coll Cardiol. 2019 Mar 19;73(10):1185-1188. doi: 10.1016/j.jacc.2019.01.012.
6
Precision medicine in heart failure no longer a visual theory but a realistic opportunity.心力衰竭的精准医学不再是一种空想理论，而是一个切实的机遇。
Eur J Intern Med. 2020 Jan;71:20-22. doi: 10.1016/j.ejim.2019.10.034. Epub 2019 Nov 11.
7
Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure.心力衰竭中迈向基于生物标志物的精准医学的逐步进展
Clin Chem. 2019 Oct;65(10):1187-1189. doi: 10.1373/clinchem.2019.308478. Epub 2019 Jul 30.
8
Induced Pluripotent Stem Cell (iPSC)-Derived Exosomes for Precision Medicine in Heart Failure.用于心力衰竭精准医学的诱导多能干细胞（iPSC）衍生外泌体
Circ Res. 2018 Mar 2;122(5):661-663. doi: 10.1161/CIRCRESAHA.118.312657.
9
The Promise and the Hype of 'Personalised Medicine'.“个性化医疗”的前景与炒作
New Bioeth. 2017 Apr;23(1):13-20. doi: 10.1080/20502877.2017.1314886.
10
Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.从心力衰竭的常规治疗向基于生物标志物的个性化精准医学转变：行动呼吁。
Eur Heart J. 2018 Aug 7;39(30):2793-2799. doi: 10.1093/eurheartj/ehx027.
引用本文的文献
1
Personalized Cell Therapy for Patients with Peripheral Arterial Diseases in the Context of Genetic Alterations: Artificial Intelligence-Based Responder and Non-Responder Prediction.基于人工智能的预测外周动脉疾病患者对个性化细胞治疗的反应者和非反应者：遗传改变背景下的个性化细胞治疗。
Cells. 2021 Nov 23;10(12):3266. doi: 10.3390/cells10123266.
本文引用的文献
1
Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3.造血干细胞衰老与心肌修复——CABG/CD133+ 骨髓造血干细胞治疗诱导的梗死后心肌再生反应的 RCT PERFECT 阶段 3 的冠心病基因型/表型分析。
EBioMedicine. 2020 Jul;57:102862. doi: 10.1016/j.ebiom.2020.102862. Epub 2020 Jul 4.
2
Combined Coronary Artery Bypass Surgery With Bone Marrow Stem Cell Transplantation: Are We There Yet?冠状动脉旁路移植术联合骨髓干细胞移植：我们做到了吗？
Ann Thorac Surg. 2019 Dec;108(6):1913-1921. doi: 10.1016/j.athoracsur.2019.05.094. Epub 2019 Aug 6.
3
Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: A meta-analysis of 14 randomized controlled trials.冠状动脉搭桥术患者的自体骨髓干细胞治疗：14项随机对照试验的荟萃分析
Exp Ther Med. 2019 Apr;17(4):2985-2994. doi: 10.3892/etm.2019.7283. Epub 2019 Feb 15.
4
COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial.比较CPM-RMI试验：近期心肌梗死患者冠状动脉搭桥术中自体骨髓来源的CD133+细胞和单个核细胞心肌内移植：一项II/III期、多中心、安慰剂对照、随机、双盲临床试验。
Cell J. 2018 Jul;20(2):267-277. doi: 10.22074/cellj.2018.5197. Epub 2018 Mar 18.
5
Cardiac Function Improvement and Bone Marrow Response -: Outcome Analysis of the Randomized PERFECT Phase III Clinical Trial of Intramyocardial CD133 Application After Myocardial Infarction.心肌内 CD133 应用治疗心肌梗死后的随机 PERFECT III 期临床试验：心功能改善和骨髓反应的结果分析。
EBioMedicine. 2017 Aug;22:208-224. doi: 10.1016/j.ebiom.2017.07.022. Epub 2017 Jul 29.
6
The IMPACT-CABG trial: A multicenter, randomized clinical trial of CD133 stem cell therapy during coronary artery bypass grafting for ischemic cardiomyopathy.IMPACT-CABG 试验：在缺血性心肌病冠状动脉旁路移植术中应用 CD133 干细胞治疗的多中心随机临床试验。
J Thorac Cardiovasc Surg. 2016 Dec;152(6):1582-1588.e2. doi: 10.1016/j.jtcvs.2016.07.067. Epub 2016 Aug 13.
7
LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis.LNK/SH2B3功能丧失促进动脉粥样硬化和血栓形成。
Circ Res. 2016 Sep 2;119(6):e91-e103. doi: 10.1161/CIRCRESAHA.116.308955. Epub 2016 Jul 18.
8
SH2B3 Is a Genetic Determinant of Cardiac Inflammation and Fibrosis.SH2B3是心脏炎症和纤维化的遗传决定因素。
Circ Cardiovasc Genet. 2015 Apr;8(2):294-304. doi: 10.1161/CIRCGENETICS.114.000527. Epub 2015 Jan 27.
9
Hypoxia-preconditioned mesenchymal stromal cells improve cardiac function in a swine model of chronic myocardial ischaemia.缺氧预处理间充质基质细胞改善慢性心肌缺血猪模型的心脏功能。
Eur J Cardiothorac Surg. 2013 May;43(5):1050-7. doi: 10.1093/ejcts/ezs549. Epub 2012 Oct 25.
10
Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells.通过对骨髓细胞进行 pim-1 工程改造，增强了心肌结构的保存。
Circ Res. 2012 Jun 22;111(1):77-86. doi: 10.1161/CIRCRESAHA.112.265207. Epub 2012 May 22.
Zotero 插件